Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 33 n° 348

Repositive Launches World-Leading Directory of Preclinical Cancer Models on Science Exchange

Posted by fidest press agency su venerdì, 25 ottobre 2019

Repositive announced that its Cancer Models Directory, containing over 5,300 preclinical cancer models, is available on Science Exchange, the widely used technology platform for outsourced R&D. This collaboration further broadens global access to Repositive’s world-leading directory of preclinical cancer models and comprehensive Cancer Models Scout service, which includes expert bioinformatic analysis to ensure the right models are identified for every customer’s research project.Repositive’s Cancer Models Directory catalogues the metadata for over 5,300 PDX and CDX models, syngeneic and humanized mouse models, GEMMs, cell lines and organoids from specialist oncology CROs around the world. Via its comprehensive, specialist and confidential Cancer Models Scout service, Repositive’s team of molecular biology and bioinformatics experts are on-hand to provide model recommendations tailored to each project’s precise requirements and search not only Repositive’s directory of models, but also its extended CRO network containing over 20,000 models. In addition, Repositive’s experts will conduct complex genomic and molecular analyses of models to find those that will be most predictive of patient response and deliver a comprehensive report outlining the best available models, including introducing pharma and biotechs to their chosen CRO to initiate project planning discussions.“We’re delighted to be collaborating with Science Exchange to increase access to our Cancer Models Directory and specialist Cancer Models Scout service amongst the translational oncology community,” said Fiona Nielsen, CEO of Repositive. “The streamlined project management, hassle-free invoicing and simple payment options offered by Science Exchange supports Repositive’s mission to make it quicker and easier for pharma and biotech researchers to access the preclinical cancer models they need to accelerate the development of effective cancer therapies.”


Inserisci i tuoi dati qui sotto o clicca su un'icona per effettuare l'accesso:

Logo di

Stai commentando usando il tuo account Chiudi sessione /  Modifica )

Google photo

Stai commentando usando il tuo account Google. Chiudi sessione /  Modifica )

Foto Twitter

Stai commentando usando il tuo account Twitter. Chiudi sessione /  Modifica )

Foto di Facebook

Stai commentando usando il tuo account Facebook. Chiudi sessione /  Modifica )

Connessione a %s...

%d blogger hanno fatto clic su Mi Piace per questo: